Real Brands, Inc.

2024 Q2 Form 10-Q Financial Statement

#000126493124000027 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.42K
YoY Change 531.55%
Cash & Equivalents $22.42K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $22.42K
YoY Change 530.89%
LONG-TERM ASSETS
Property, Plant & Equipment $1.055M
YoY Change -7.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $125.0K
YoY Change
Other Assets $530.00
YoY Change 0.0%
Total Long-Term Assets $1.180M
YoY Change 3.74%
TOTAL ASSETS
Total Short-Term Assets $22.42K
Total Long-Term Assets $1.180M
Total Assets $1.203M
YoY Change 5.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $756.00
YoY Change -99.84%
Accrued Expenses $997.0K
YoY Change 35.08%
Deferred Revenue
YoY Change
Short-Term Debt $952.8K
YoY Change 43.58%
Long-Term Debt Due $25.04K
YoY Change
Total Short-Term Liabilities $2.571M
YoY Change 33.13%
LONG-TERM LIABILITIES
Long-Term Debt $72.51K
YoY Change -39.46%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $72.51K
YoY Change -39.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.571M
Total Long-Term Liabilities $72.51K
Total Liabilities $2.644M
YoY Change 28.89%
SHAREHOLDERS EQUITY
Retained Earnings -$14.06M
YoY Change 5.49%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.441M
YoY Change
Total Liabilities & Shareholders Equity $1.203M
YoY Change 5.38%

Cashflow Statement

Concept 2024 Q2 2024 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NONE
CY2024Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
usd
CY2023Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
usd
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
usd
CY2024Q1 us-gaap Revenues
Revenues
usd
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001084133
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
usd
CY2024Q1 us-gaap Revenues
Revenues
usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2024Q1 us-gaap Certain Loans Acquired In Transfer Not Accounted For As Debt Securities Allowance For Loan Losses
CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesAllowanceForLoanLosses
usd
CY2023Q4 us-gaap Certain Loans Acquired In Transfer Not Accounted For As Debt Securities Allowance For Loan Losses
CertainLoansAcquiredInTransferNotAccountedForAsDebtSecuritiesAllowanceForLoanLosses
usd
CY2021Q4 RLBD Extended Maturity Date
ExtendedMaturityDate
P2Y
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-24115
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
REAL BRANDS INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
40-0014655
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12 Humbert Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
North Providence
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02911
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
803-0004
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2690640226 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22422 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79345 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
22422 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
79345 usd
CY2024Q1 us-gaap Deposits
Deposits
530 usd
CY2023Q4 us-gaap Deposits
Deposits
530 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1054644 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1075262 usd
CY2024Q1 us-gaap Investments
Investments
125000 usd
CY2023Q4 us-gaap Investments
Investments
125000 usd
CY2024Q1 us-gaap Assets
Assets
1202596 usd
CY2023Q4 us-gaap Assets
Assets
1280137 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
550905 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
550851 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
996961 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
930930 usd
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
215672 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
215672 usd
CY2024Q1 us-gaap Loans Payable
LoansPayable
394105 usd
CY2023Q4 us-gaap Loans Payable
LoansPayable
394105 usd
CY2024Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
300000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
300000 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
43003 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
43003 usd
CY2024Q1 us-gaap Discontinued Operation Amounts Of Material Contingent Liabilities Remaining
DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining
45625 usd
CY2023Q4 us-gaap Discontinued Operation Amounts Of Material Contingent Liabilities Remaining
DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining
45625 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2571311 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2505226 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
72505 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
78718 usd
CY2024Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
72505 usd
CY2023Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
78718 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2643816 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2583946 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3998000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3998000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2690640226 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2690640226 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2690640226 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2690640226 shares
CY2024Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
2690640 usd
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
2690640 usd
CY2024Q1 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
6806011 shares
CY2023Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
6806011 shares
CY2024Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
96403 usd
CY2023Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
96403 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9830710 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50710 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65426 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
72000 usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
6213 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5865 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6213 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66135 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-56923 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
708 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79345 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9816056 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14058973 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13906906 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1441220 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1303807 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1202596 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1280137 usd
CY2023Q1 us-gaap Revenues
Revenues
22247 usd
CY2023Q1 us-gaap Revenues
Revenues
22247 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
4247 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50948 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
630534 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
19400 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
13000 usd
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
44036 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
81061 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
114384 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
724596 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-114384 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-720348 usd
CY2024Q1 us-gaap Depreciation
Depreciation
20618 usd
CY2023Q1 us-gaap Depreciation
Depreciation
20618 usd
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
17065 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
11611 usd
CY2024Q1 us-gaap Other Income
OtherIncome
-37683 usd
CY2023Q1 us-gaap Other Income
OtherIncome
-32228 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-152067 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-752577 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
152067 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
752577 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2690640226 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2690640226 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-752895 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
595445 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
752577 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-910027 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1303807 usd
CY2024Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
14654 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
152067 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1441220 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
152067 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
752577 usd
CY2024Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
14654 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
595445 usd
CY2024Q1 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
20618 usd
CY2023Q1 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
20618 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
750 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
66085 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
70338 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2845 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22422 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3553 usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
1572 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
1920 usd
CY2013Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
150:1 Reverse Stock Split
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
152067 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
752577 usd
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22422 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
79345 usd
CY2024Q1 us-gaap Capital
Capital
2548889 usd
CY2023Q4 us-gaap Capital
Capital
2425811 usd
CY2024Q1 RLBD Capital Increase Decrease
CapitalIncreaseDecrease
123008 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zDLNLNRvPqA" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of estimates and judgments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Key areas of estimation include the estimated useful lives of property, plant, equipment and intangibles assets and liabilities, income taxes, and the valuation of stock-based compensation. Due to the uncertainty inherent in such estimates, actual results may differ from the Company’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <br/> </p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"> </p>
CY2024Q1 us-gaap Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts
FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
<p id="xdx_84D_eus-gaap--FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_zLnKKEI4XU9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable and Allowance for Doubtful Accounts</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company performs periodic credit evaluations of its customers’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zpcL7iZIlGql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
CY2020Q1 RLBD Shares Issued Of Aquisition Company
SharesIssuedOfAquisitionCompany
2000000 shares
CY2020Q1 RLBD Mortgage Assumption
MortgageAssumption
189916 usd
CY2021Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
475000 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7521 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
CY2024Q1 us-gaap Other Real Estate Non Covered Period Increase Decrease
OtherRealEstateNonCoveredPeriodIncreaseDecrease
13097 usd
CY2024Q1 us-gaap Depreciation
Depreciation
20618 usd
CY2024Q1 us-gaap Option Indexed To Issuers Equity Indexed Shares
OptionIndexedToIssuersEquityIndexedShares
352891447 shares
CY2024Q1 us-gaap Ownshare Lending Arrangement Shares Outstanding
OwnshareLendingArrangementSharesOutstanding
42639222 shares
CY2023Q1 us-gaap Option Indexed To Issuers Equity Indexed Shares
OptionIndexedToIssuersEquityIndexedShares
300173307 shares
CY2023Q1 us-gaap Ownshare Lending Arrangement Shares Outstanding
OwnshareLendingArrangementSharesOutstanding
30622108 shares
CY2024Q1 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
50%
CY2021Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
475000 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7521 usd
CY2021Q4 RLBD Year Of Depreciation For Improvements
YearOfDepreciationForImprovements
P15Y
CY2024Q1 us-gaap Other Real Estate Non Covered Period Increase Decrease
OtherRealEstateNonCoveredPeriodIncreaseDecrease
13097 usd
CY2024Q1 us-gaap Depreciation
Depreciation
20618 usd
CY2024Q1 us-gaap Inventory Buildings And Improvements
InventoryBuildingsAndImprovements
475000 usd
CY2023Q4 us-gaap Inventory Buildings And Improvements
InventoryBuildingsAndImprovements
475000 usd
CY2024Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
785823 usd
CY2023Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
785823 usd
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1260823 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1260823 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
206178 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
185560 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1054644 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1075262 usd
CY2023Q3 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
2206 shares
CY2023Q3 us-gaap Investments
Investments
125000 usd
CY2023Q3 us-gaap Investment Owned Percent Of Net Assets
InvestmentOwnedPercentOfNetAssets
0.02 pure
CY2023Q3 RLBD Real Brand Granted Distribution
RealBrandGrantedDistribution
0.03 pure
CY2023Q3 us-gaap Investment Company Equity Security Fv Ni Contractual Sale Restriction Remaining Period
InvestmentCompanyEquitySecurityFvNiContractualSaleRestrictionRemainingPeriod
P3Y
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0 shares
CY2015Q4 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
71069 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
131294 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
140769 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
387655 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
392278 usd
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
31200 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
17332 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
756 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
472 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
550905 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
550851 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
996961 usd
CY2024Q1 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
200000 usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
1572 usd
CY2024Q1 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
7 pure
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
62753 usd
CY2024Q1 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
7 pure
CY2024Q1 us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
200000 usd
CY2021Q4 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
7 pure
CY2021Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.50
CY2021Q4 RLBD Percentage Own Converted1
PercentageOwnConverted1
1 pure
CY2024Q1 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
1000000 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2025Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.01
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2690640226 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
2000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
38861768 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0035
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.0035
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
500000 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
94654420 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.007
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.007
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
595445 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
352891447 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
294029679 shares
CY2024Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
14654 usd
CY2019 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
175000 usd
CY2024Q2 us-gaap Option Indexed To Issuers Equity Indexed Shares
OptionIndexedToIssuersEquityIndexedShares
25000000 shares
CY2024Q2 RLBD Options Price Time
OptionsPriceTime
stock options at an exercise price at the volume weighted average price of the Company’s common stock for the 30 days prior to the announcement of the transaction. The term of the option is 5 years

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001264931-24-000027-index-headers.html Edgar Link pending
0001264931-24-000027-index.html Edgar Link pending
0001264931-24-000027.txt Edgar Link pending
0001264931-24-000027-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
real10q124.htm Edgar Link pending
report.css Edgar Link pending
rlbd-20240331.xsd Edgar Link pending
Show.js Edgar Link pending
rlbd-20240331_def.xml Edgar Link unprocessable
rlbd-20240331_lab.xml Edgar Link unprocessable
rlbd-20240331_pre.xml Edgar Link unprocessable
real10q124_htm.xml Edgar Link completed
rlbd-20240331_cal.xml Edgar Link unprocessable